U-Neuron Biomedical

U-Neuron Biomedical ROE

The Return on Equity (ROE) of U-Neuron Biomedical (6973.TWO) as of Oct 17, 2026 is -7.39 %. In the previous year, Return on Equity (ROE) was -17.26 % — a change of -57.17% (higher).

ROE

-7.39 %

YoY

-57.17%

Last updated:

In 2024, U-Neuron Biomedical's return on equity (ROE) was -7.39 %, a -57.17% increase from the -17.26 % ROE in the previous year.

The U-Neuron Biomedical ROE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROE
Date
ROE
Jan 1, 2021
-5.76 TWD
Jan 1, 2022
-26.44 TWD
Jan 1, 2023
-17.26 TWD
Jan 1, 2024
-7.39 TWD
The U-Neuron Biomedical ROE history
YEARROEYoY
-7.39 %-57.17%
-17.26 %-34.74%
-26.44 %+359.03%
-5.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

U-Neuron Biomedical Stock analysis

What does U-Neuron Biomedical do? U-Neuron Biomedical Inc, headquartered in Taipei, Taiwan, operates in the Health Care sector within the Biotechnology industry. The company, listed on 20 July 2023, develops cosmetics, health care consumer products, and new drugs. Its drug development focuses on allogeneic amniotic fluid stem cells for applications like erectile dysfunction (UA002) and dry eye (UB003). Cosmetic products, featuring deer amniotic fluid stem cell derivatives, include anti-aging masks, essences, and creams for repair and hydration, primarily sold domestically in Taiwan. U-Neuron Biomedical is one of the most popular companies on Eulerpool.

ROE Details

Decoding U-Neuron Biomedical's Return on Equity (ROE)

U-Neuron Biomedical's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing U-Neuron Biomedical's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

U-Neuron Biomedical's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in U-Neuron Biomedical’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about U-Neuron Biomedical stock

Return on Equity (ROE) of U-Neuron Biomedical is -7.39 % in 2024.

Return on Equity (ROE) of U-Neuron Biomedical changed from -17.26 % to -7.39 %, representing a -57.17% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Equity (ROE) U-Neuron Biomedical since 2006 – with annual values, charts, and detailed analysis.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Equity (ROE)'s U-Neuron Biomedical with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Equity (ROE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Equity (ROE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — U-Neuron Biomedical

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — U-Neuron Biomedical